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Abstract
Recent population studies suggest a role of smoking in the etiology of breast cancer, but few have been conducted among 
African American women. In a collaborative project of four large studies, we examined associations between smoking 
measures and breast cancer risk by menopause and hormone receptor status [estrogen receptor-positive (ER+), ER-negative 
(ER−) and triple-negative (ER−, PR−, HER2−)]. The study included 5791 African American women with breast cancer and 
17 376 African American controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated in multivariable 
logistic regression analysis with adjustment for study and risk factors. Results differed by menopausal status. Among 
postmenopausal women, positive associations were observed for long duration and greater pack-years of smoking: relative 
to never smoking, fully adjusted ORs were 1.14 (95% CI: 1.03–1.26) for duration ≥20 years and 1.16 (95% CI: 1.01–1.33) for ≥20 
pack-years. By contrast, inverse associations were observed among premenopausal women, with ORs of 0.80 (95% CI: 0.68–
95) for current smoking and 0.81 (95% CI: 0.69–0.96) for former smoking, without trends by duration. Associations among 
postmenopausal women were somewhat stronger for ER+ breast cancer. The findings suggest that the relation of cigarette 
smoking to breast cancer risk in African American women may vary by menopausal status and breast cancer subtype.
Introduction
The epidemiological evidence for an association between cigarette 
smoking and breast cancer risk has been inconsistent, leading to 
the conclusion in the past that smoking was not a risk factor for 
this type of cancer (1,2). However, more recent evidence seems 
to support a role of smoking in the etiology of breast cancer (3–5) 
with some studies finding the greatest increases for long-duration 
smoking begun at an early age or before the first birth (5). In 2012, 
the International Agency for Research on Cancer (IARC) Monographs 
indicated that there is a positive association between tobacco smok-
ing and breast cancer (6). In addition, the recent report from the US 
Surgeon General stated that a history of ever smoking was associ-
ated with an average of 10% increase in risk of breast cancer (7).
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It is possible that associations of smoking with cancer out-
comes differ by race. In the Multiethnic Cohort Study, Haiman 
and colleagues found that, among those who smoked less 
than 30 cigarettes per day, African Americans had signifi-
cantly greater risks of lung cancer than European Americans, 
Asians and Hispanics (8). Also, African Americans had higher 
levels of total nicotine equivalents than other populations 
controlling for cigarettes per day (9). Such differences may 
be due to a number of factors including differences in smok-
ing behavior, such as depth of inhalation (10) which could 
result in greater exposure to tobacco-smoke carcinogens, or 
differences in genetic variants related to carcinogen metab-
olism, DNA repair and/or other pathways that may confer 
greater susceptibility to carcinogenesis. Results of the two 
studies examining relationships of smoking with breast 
cancer among African American women have been incon-
sistent (11,12). Because African Americans have higher rates 
of premenopausal breast cancer compared with European 
Americans women, and greater proportions of estrogen 
receptor-negative (ER−) tumors associated with an aggres-
sive pathology and poor prognosis (13), we aimed to investi-
gate whether cigarette smoking is related to increased risk in 
these subgroups of breast cancer in African American women. 
In a collaborative project of four large studies with African 
American women, we examined associations between smok-
ing exposure and breast cancer risk by hormone receptor sta-
tus and menopausal status.
Materials and methods
Study population
The African American Breast Cancer Epidemiology and Risk (AMBER) 
Consortium was designed to elucidate the reasons for disparities in 
breast cancer subtypes among African American women. The details of 
AMBER have been published elsewhere (14). In brief, AMBER consists 
of two case–control studies, the Carolina Breast Cancer Study (CBCS) 
(15,16) and the Women’s Circle of Health Study (WCHS) (17,18), and two 
cohort studies, the Black Women’s Health Study (BWHS) (19) and the 
Multiethnic Cohort Study (MEC) (20). Diagnosis years (age range) were 
1993–2014 (20–74 years) in CBCS and 2002–2013 (20–75 years) in WCHS. 
Enrollment years were 1995 (21–69 years) in BWHS and 1993–1996 (45–
75 years) in MEC. Institutional Review Board approval was granted for 
each individual study and for the AMBER Consortium, and informed 
consent was provided by all study participants. The cohort studies pro-
vided nested case–control data with approximately four controls ran-
domly selected from among women without breast cancer, matched on 
year of birth and on having completed the same questionnaire as the 
last questionnaire completed by the case before her diagnosis (index 
date) of breast cancer. The nested case–control data from BWHS and 
MEC were pooled with case–control data from CBCS and WCHS to create 
an AMBER database.
Cases of breast cancer
Eligible cases for the present study were 5819 women with a first diagnosis 
of invasive breast cancer or ductal carcinoma in situ and 17 453 controls. 
For the present study, individuals with missing data on smoking status 
(n = 105) were excluded, leaving 5791 cases and 17 376 controls. Pathology 
data from hospital records or cancer registry records were used to classify 
cancers by subtype based on ER, progesterone receptor (PR) and human 
epidermal receptor 2 (HER2). In the present study, 3099 ER-positive (ER+), 
1511 ER− and 694 triple-negative (ER−, PR−, HER2−) cases were included.
Smoking measures
Smoking measures included smoking status (never, former, current), 
age at smoking initiation (≤14, 15–17, 18–20, ≥21 years), average number 
of cigarettes per day (<5, 5–14, 15–24, ≥25), smoking duration (<10, 10–19, 
≥20 years), pack-years (<10, 10–19, ≥20) and years smoked prior to first birth 
among parous women (calculated by subtracting age at smoking initiation 
from age at first birth; smoked after first birth only, 1–5, 6–9, ≥10 years).
Statistical analysis
Distributions of smoking exposures between cases and controls were 
compared by chi-square tests. Associations between smoking and breast 
cancer were assessed by calculating odds ratios (ORs) and 95% confidence 
intervals (95% CIs) using unconditional logistic regression models. Never 
smokers were used as the common reference group. Basic models were 
adjusted for age (years), study (four studies), calendar year of interview 
(1993–1998, 1999–2005, 2006–2013) and geographic region (Northeast-NJ, 
Northeast-excluding NJ, South, Midwest, West and other). Multivariate 
models were further adjusted for education (<12, 12, 13–15, 16, ≥17 years, 
unknown), age at menarche (<11, 11–12, 13–14, 15–16, ≥17 years, unknown), 
age at first birth (<18, 18–19, 20–24, 25–29, 30–34, ≥35 years, unknown), parity 
(nulliparous, 1–2, 3–4, ≥5, unknown), age at menopause (<45, 45–49, 50–54, 
≥55  years, unknown), oral contraceptive use (never/<1, 1–9, ≥10  years, 
unknown), estrogen only use (never, <5, ≥5 years, unknown), estrogen and 
progesterone use (never, <5, ≥5 years, unknown), body mass index (<18.5, 
18.5–24.9, 25–29.9, 30–34.9, 35–39.9, ≥40 kg/m2, unknown), family history of 
breast cancer (yes, no) and alcohol consumption (never; past; current: <1; 
current: 1–6; current: ≥7 drinks/week; unknown). For each covariate, there 
was <2% missing data. In analyses limited to participants without miss-
ing data on any covariate (n = 19 669; 85%), the results did not change. We 
also included the study and the year of interview as random effects in the 
models, but the result did not vary. For analyses of passive smoking, we 
excluded MEC due to lack of information. Women who had never been 
exposed to active or passive smoking at home were used as the refer-
ence group. Tests for linear trend were performed by entering the ordinal 
variable as continuous parameter in the models, excluding never smokers. 
Tests for interaction were performed using Wald statistics for cross-terms. 
P values were two sided and were considered statistically significant if 
<0.05. All analyses were performed with SAS, version 9.4 (SAS Institute, 
Cary, NC).
Results
As shown in Table 1, the CBCS had the highest proportion of 
ER− and triple-negative cases, due to oversampling of young 
women, and the MEC had the highest proportion of older 
women. Proportions of current smokers among controls ranged 
from 18.3 in BWHS to 20.7 in WCHS. The proportion of former 
smokers was higher in MEC (34.4) than in the other three stud-
ies (19.7–23.4), which likely reflects the high proportions of older 
women in MEC.
Table 2 presents results from a basic model (adjustment 
for age, study, year and geographic region) and fully adjusted 
models for associations between smoking measures and overall 
risk of ER+, ER− and triple-negative breast cancer. There was lit-
tle difference in ORs from the basic and multivariate models. 
Results were similar for each cancer subtype, with few excep-
tions. Neither former nor current smoking was associated with 
risk for ER+, ER− or triple-negative breast cancer. Results were 
Abbreviations 
AMBER African American Breast Cancer Epidemiology  
 and Risk 
BWHS Black Women’s Health Study 
CBCS Carolina Breast Cancer Study 
CI confidence interval 
ER estrogen receptor 
HER2 human epidermal receptor 2 
IARC International Agency for Research on Cancer 
MEC Multiethnic Cohort Study 
OR odds ratio 
PR progesterone receptor 
WCHS Women’s Circle of Health Study
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null for all measures of smoking among the combined group 
of current and former smokers except duration: there was evi-
dence of an increasing risk with increasing duration of smoking 
for ER+ breast cancer (OR for ≥20 years duration: 1.11, 95% CI: 
1.00–1.23; P trend for duration categories = 0.033), but no trend 
observed for ER− or triple-negative breast cancer.
Table 3 presents data for all subtypes together, stratified by 
menopausal status. ORs from the basic and multivariate models 
were very similar. Among postmenopausal women, the OR for 
current relative to never smokers was 1.05 (95% CI: 0.94–1.17), 
with fully adjusted OR of 1.07 (95% CI: 0.95–1.20). Among pre-
menopausal women, there appeared to be inverse associations 
for current versus never smokers (OR = 0.79, 95% CI: 0.68–0.92; 
fully adjusted OR = 0.80, 95% CI: 0.68–0.95). Among postmeno-
pausal women, smoking duration and pack-years of ≥20 were 
associated with non-significant increases in risk (adjusted OR 
for ≥20 years duration = 1.14, 95% CI: 1.03–1.26); adjusted OR for 
≥20 pack-years = 1.16, 95% CI: 1.01–1.33) compared with never 
smoking. By contrast, among premenopausal women, adjusted 
ORs for duration ≥20 years and pack-years ≥20 were 0.78 (95% CI: 
0.64–0.94) and 0.91 (95% CI: 0.67–1.22), respectively, with similar 
estimates in basic and fully adjusted models. For initiation of 
smoking before age 15 relative to never smoking, ORs were 1.01 
(95% CI: 0.82–1.25) in postmenopausal women and 0.73 (95% CI: 
0.54–0.98) in premenopausal women. Although tests for inter-
action by menopausal status were statistically significant for 
all smoking measures except years smoked before first birth, 
the P values for interaction largely reflected the differences in 
association for ever smoking versus never smoking rather than 
differences for the heaviest categories of smoking exposure. We 
also looked at joint exposures based on findings from previous 
studies. In a combined analysis of age at initiation of smoking 
and pack-years, ORs for smoking initiation at ≤17 years and ≥20 
pack-years of smoking compared with never smoking were 1.19 
(95% CI: 0.84–1.70) in premenopausal women and 1.07 (95% CI: 
0.87–1.32) in postmenopausal women (data not shown). In a 
combined analysis of total pack-years with years smoked before 
first birth, ORs for ≥6  years smoked before first birth and ≥20 
pack-years compared with parous never smokers were 0.89 (95% 
CI: 0.53–1.48) in premenopausal women and 1.07 (95% CI: 0.82–
1.40) in postmenopausal women (data not shown). Results did 
not vary when we restricted the analyses to invasive cases only 
(78% of the cases, data not shown).
In analyses stratified on study design (case–control versus 
cohort) of the original contributing studies, the inverse asso-
ciation observed for current smoking in premenopausal women 
was stronger in the case–control (OR = 0.68, 95% CI: 0.52–0.89) 
than in the cohort studies (OR = 0.88, 95% CI: 0.71–1.08), but a 
test for heterogeneity was not statistically significant (P = 0.64). 
Among postmenopausal women, ORs for current smoking were 
1.00 (95% CI: 0.77–1.29) in the case–control studies and 1.08 (95% 
CI: 0.95–1.23) in the cohort studies.
We repeated the analyses after excluding passive smokers 
from the reference category (data not shown). The ORs for pas-
sive only relative to never active and never passive were 1.10 
(95% CI: 0.94–1.30) among premenopausal women and 0.93 (95% 
CI: 0.79–1.10) among postmenopausal women. Estimates for 
active smoking relative to never active and never passive were 
similar to the estimates based on a reference group of never 
active smokers.
We next assessed associations with ER+, ER− and triple-neg-
ative breast cancer within strata of menopausal status (Tables 
4 and 5). Among premenopausal women (Table 4), results were 
generally similar for ER+ and ER− cancer with a few exceptions: 
ORs for ≥20 pack-years versus none were 1.13 (95% CI: 0.78–1.64) 
for ER+ and 0.55 (95% CI: 0.30–1.01) for ER−, and ORs for ≥25 cig-
arettes per day were 1.09 (95% CI: 0.67–1.78) and 0.66 (95% CI: 
0.33–1.32) for ER+ and ER−, respectively. Among postmenopausal 
women, there was some evidence of stronger associations for 
ER+ than ER− breast cancer. The OR for ≥20 years duration was 
1.17 (95% CI: 1.04–1.32) for ER+ cancer and 1.03 (95% CI: 0.86–
1.24) for ER− cancer (Table 5). The OR for ≥10 years of smoking 
before first birth was 1.20 (95% CI: 0.90–1.59) for ER+ and 0.93 
(95% CI: 0.59–1.47) for ER− cancer. ORs for triple-negative tumors 
were similar to those for ER− breast cancer.
Associations between smoking and breast cancer did not dif-
fer between alcohol drinkers and non-drinkers in pre- or post-
menopausal women (data not shown).
Discussion
In this collaborative study of breast cancer in African American 
women, associations between cigarette smoking and breast 
cancer risk differed by menopausal status. Among postmeno-
pausal women, smoking duration of ≥20 years and pack-years 
of ≥20 were related to a 14 and 16% increased breast cancer risk, 
Table 1. Characteristics of breast cancer cases and controls by study
CBCS WCHS MEC BWHS Total
n (%) n (%) n (%) n (%) n (%)
Breast cancer cases
 Total 894 1406 1138 2353 5791
 ER+ 405 (45.3) 813 (57.8) 692 (60.8) 1189 (50.5) 3099 (53.5)
 ER− 401 (44.9) 313 (22.3) 244 (21.4) 553 (23.5) 1511 (26.1)
 ER−, PR−, HER2− 233 (26.1) 182 (12.9) 95 (8.3) 184 (7.8) 694 (12.0)
 Missing 88 (9.8) 280 (19.9) 202 (17.8) 611 (26.0) 1181 (20.4)
Age at diagnosis (years)
 <40 139 (15.6) 162 (11.5) 0 (0.0) 182 (7.7) 483 (8.3)
 40–49 289 (32.3) 395 (28.1) 16 (1.4) 690 (29.3) 1390 (24.0)
 50–59 212 (23.7) 484 (34.4) 171 (15.0) 759 (32.3) 1626 (28.1)
 ≥60 254 (28.4) 365 (26.0) 951 (83.6) 722 (30.7) 2292 (39.6)
Smoking status among controls
 Total 788 1221 4590 10 777 17 376
 Never 470 (59.6) 705 (57.7) 2160 (47.1) 6285 (58.3) 9620 (55.4)
 Former 155 (19.7) 270 (22.1) 1577 (34.4) 2519 (23.4) 4521 (26.0)
 Current 163 (20.7) 246 (20.2) 853 (18.6) 1973 (18.3) 3235 (18.6)
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respectively, and associations were more apparent for ER+ than 
for ER− cancer. The magnitude of the associations is quite mod-
est compared to the relationship between smoking and lung 
cancer risk, where smoking duration ≥20 years and pack-years 
≥20 are associated with more than 240 and 490% increased risk of 
lung cancer, respectively, in women (21). Among premenopausal 
women, measures of smoking duration and intensity were not 
associated with increased risk of breast cancer and results were 
similar for ER+, ER− and triple-negative breast cancer. Former 
and current smoking were associated with an approximately 
20% reduction in risk, but without a clear dose–response rela-
tionship in any of the smoking variables.
Evidence for an effect of cigarette smoking on breast can-
cer risk is still ‘insufficient’ in humans, according to the IARC 
Monographs (22). Historically, most studies found no link 
between cigarette smoking and breast cancer (23), but in recent 
years, more studies have found that smoking is related to a 
higher risk of breast cancer (3,4). A meta-analysis of 15 cohort 
studies in 2013 showed a 12% increase in risk among current 
smokers and a 9% increase among former smokers, compared 
with never smokers (5), whereas a collaborative re-analysis in 
2002 concluded that smoking had no effect on the risk of devel-
oping breast cancer (24). The 2013 meta-analysis also reported 
that smoking initiation at a younger age and before the first birth 
was associated with a higher risk of breast cancer, and an expert 
panel convened by four Canadian agencies, the Ontario Tobacco 
Research Unit, the Public Health Agency of Canada, Physicians 
for a Smoke-Free Canada and the Canadian Partnership Against 
Cancer, concluded that the association between active smok-
ing and breast cancer is consistent with causality (3). Recently, 
several cohort (12,25–28) and population-based case–control 
(29,30) studies found an increased risk associated with various 
smoking measures, whereas one cohort (31) and one popula-
tion-based case–control (32) study found no association with 
any smoking variable. However, there are few data for African 
American women.
Results from studies on smoking in relation to pre- and post-
menopausal breast cancer are mixed (6,7). IARC Monographs 
in 2012 stated that results for pre- versus post-menopausal 
breast cancer were inconsistent (6). The US Surgeon General 
Report in 2014 concluded that, although a meta-analysis of 
20 studies suggested greater risk in premenopausal than in 
Table 4. Smoking and breast cancer risk by tumor subtype in premenopausal women
n controls
ER+ ER− ER−, PR−, HER2−
n cases OR (95% CI)a n cases OR (95% CI)a n cases OR (95% CI)a
Never smokers 3532 641 1.00 (ref) 384 1.00 (ref) 175 1.00 (ref)
Smoking status
 Former 875 128 0.75 (0.60–0.95) 95 0.94 (0.72–1.23) 44 0.94 (0.64–1.38)
 Current 992 165 0.87 (0.70–1.08) 89 0.69 (0.52–0.91) 51 0.82 (0.57–1.20)
Former/current smokers
Age at smoking initiation (years)
 ≥21 514 74 0.77 (0.58–1.02) 49 0.79 (0.56–1.12) 23 0.83 (0.50–1.37)
 18–20 559 77 0.74 (0.56–0.98) 47 0.69 (0.48–0.97) 27 0.87 (0.55–1.39)
 15–17 531 97 0.92 (0.70–1.19) 64 0.98 (0.71–1.35) 33 0.96 (0.62–1.50)
 ≤14 240 44 0.87 (0.60–1.26) 23 0.78 (0.48–1.26) 12 0.80 (0.41–1.56)
 P for trendb 0.16 0.38 0.79
Cigarettes per day
 <5 558 75 0.78 (0.59–1.04) 38 0.82 (0.56–1.18) 21 1.11 (0.66–1.84)
 5–14 796 117 0.71 (0.56–0.90) 81 0.79 (0.59–1.05) 44 0.88 (0.59–1.30)
 15–24 369 76 0.99 (0.74–1.33) 53 0.87 (0.61–1.23) 26 0.80 (0.49–1.32)
 ≥25 125 23 1.09 (0.67–1.78) 11 0.66 (0.33–1.32) 4 0.47 (0.16–1.43)
 P for trendb 0.16 0.72 0.16
Smoking duration (years)
 <10 582 85 0.83 (0.63–1.07) 58 0.76 (0.55–1.05) 36 1.04 (0.68–1.59)
 10–19 624 87 0.80 (0.62–1.04) 63 0.91 (0.67–1.25) 26 0.77 (0.48–1.24)
 ≥20 625 119 0.82 (0.64–1.05) 62 0.77 (0.56–1.07) 32 0.80 (0.51–1.25)
 P for trendb 0.95 0.97 0.47
Pack-years
 <10 1180 170 0.76 (0.62–0.93) 110 0.78 (0.61–1.00) 64 0.96 (0.68–1.35)
 10–19 431 74 0.83 (0.62–1.11) 59 0.98 (0.70–1.37) 24 0.80 (0.49–1.32)
 ≥20 214 45 1.13 (0.78–1.64) 13 0.55 (0.30–1.01) 6 0.50 (0.20–1.22)
 P for trendb 0.068 0.60 0.11
Year smoked before first birthc
 Never smokers 2472 487 1.00 (ref) 308 1.00 (ref) 143 1.00 (ref)
 Smoked after only 404 64 0.69 (0.50–0.96) 51 0.73 (0.50–1.06) 26 0.79 (0.47–1.33)
 1–5 491 69 0.75 (0.55–1.02) 60 0.99 (0.71–1.40) 31 1.00 (0.62–1.60)
 6–9 231 41 0.86 (0.59–1.27) 26 0.98 (0.61–1.57) 10 0.68 (0.33–1.42)
 ≥10 332 58 0.84 (0.60–1.19) 19 0.58 (0.34–0.99) 13 0.97 (0.49–1.92)
 P for trendb 0.087 0.31 0.48
aAdjusted for age, study, time period, geographic region, education, age at menarche, age at first birth, parity, oral contraceptive use, estrogen only use, estrogen and 
progesterone use, body mass index, family history of breast cancer and alcohol consumption.
bExcluding never smokers.
cAmong parous women.
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postmenopausal women, it remained uncertain whether the 
association of smoking with breast cancer differed by menopau-
sal status (7). In the present study of African American women, 
we found inconsistent directions in the associations with smok-
ing exposures by menopausal status, with inverse associations 
between smoking and risk of premenopausal breast cancer and 
positive associations with postmenopausal cancer. We can only 
speculate as to the biologic mechanisms that could be at play to 
explain reduced risk with smoking in younger African American 
women with breast cancer. It has been shown in numerous stud-
ies that serum estradiol levels are significantly higher across the 
menstrual cycle in African American compared with Caucasian 
women (33), particularly in premenopausal women (reviewed 
in reference), and that serum hormone levels differ according 
to smoking status, with lower estradiol and estrone among 
premenopausal women who are smokers (34). In the Women’s 
Health Initiative, smoking was associated with increased risk of 
infertility and natural menopause occurring before the age of 
50 years (35), illustrating effects on reproductive and hormonal 
factors. Smoking has been shown to exert estrogen-lowering 
effects in premenopausal women through the action of nicotine 
on increasing the number of regressing follicles in the ovary and 
blocking the aromatase enzyme, leading to a decreased conver-
sion of androgens to estrogens (36).
Because African American women have higher estrogen lev-
els throughout the menstrual cycle than Caucasians and have 
greater prevalence of premenopausal breast cancer, it may be 
plausible to suggest that potential anti-estrogenic effects of cig-
arette smoking, by reducing levels of estradiol and estrone, could 
reduce risk of premenopausal breast cancer in African American 
women. This reduction in estrogen levels in premenopausal 
women may outweigh an increased risk due to the carcino-
gens in cigarette smoke. To our knowledge, inverse associations 
between smoking and premenopausal breast cancer have not 
been previously reported, and these findings among premeno-
pausal African American women merit further investigation. 
In contrast to the findings in premenopausal women, among 
postmenopausal women in our study, longer duration of smok-
ing was related to an increased risk of breast cancer. Tobacco 
smoking is associated with higher levels of sex hormones in 
postmenopausal women (37), which may partly explain the link 
between tobacco and breast cancer risk, apart from its direct 
Table 5. Smoking and breast cancer risk by tumor subtype in postmenopausal women
n controls
ER+ ER− ER−, PR−, HER2−
n cases OR (95% CI)a n cases OR (95% CI)a n cases OR (95% CI)a
Never smokers 5441 1000 1.00 (ref) 415 1.00 (ref) 180 1.00 (ref)
Smoking status
 Former 3389 611 1.04 (0.92–1.17) 259 1.11 (0.93–1.33) 120 1.17 (0.90–1.51)
 Current 2021 365 1.12 (0.97–1.30) 145 0.93 (0.75–1.16) 68 0.97 (0.71–1.34)
Former/current smokers
Age at smoking initiation (years)
 ≥21 2621 448 1.03 (0.90–1.18) 170 1.01 (0.83–1.24) 77 1.08 (0.80–1.46)
 18–20 1305 254 1.14 (0.97–1.34) 110 1.08 (0.85–1.38) 52 1.17 (0.83–1.65)
 15–17 868 165 1.08 (0.89–1.32) 81 1.13 (0.86–1.48) 39 1.17 (0.79–1.74)
 ≤14 439 90 1.13 (0.87–1.46) 37 1.01 (0.69–1.47) 19 1.03 (0.60–1.75)
 P for trendb 0.56 0.68 0.69
Cigarettes per day
 <5 1469 257 1.09 (0.93–1.27) 107 1.11 (0.88–1.41) 51 1.26 (0.90–1.77)
 5–14 1966 373 1.09 (0.95–1.26) 151 1.04 (0.84–1.28) 70 1.05 (0.77–1.43)
 15–24 1336 261 1.13 (0.96–1.33) 91 0.92 (0.71–1.18) 42 0.96 (0.66–1.38)
 ≥25 511 72 0.83 (0.63–1.09) 49 1.20 (0.86–1.68) 21 1.15 (0.69–1.90)
 P for trendb 0.23 0.67 0.55
Smoking duration (years)
 <10 1046 170 1.01 (0.84–1.21) 83 1.12 (0.87–1.46) 37 1.16 (0.79–1.71)
 10–19 1147 176 0.92 (0.76–1.10) 81 1.03 (0.79–1.34) 41 1.21 (0.84–1.75)
 ≥20 3017 611 1.17 (1.04–1.32) 231 1.03 (0.86–1.24) 106 1.04 (0.79–1.37)
 P for trendb 0.023 0.64 0.68
Pack-years
 <10 2351 432 1.03 (0.90–1.18) 188 1.05 (0.86–1.27) 91 1.12 (0.85–1.49)
 10–19 1569 301 1.18 (1.01–1.38) 113 1.02 (0.81–1.28) 53 1.09 (0.77–1.53)
 ≥20 1211 214 1.07 (0.90–1.27) 90 1.10 (0.85–1.42) 37 1.04 (0.71–1.54)
 P for trendb 0.42 0.67 0.81
Years smoked before first birthc
 Never smokers 4575 858 1.00 (ref) 375 1.00 (ref) 167 1.00 (ref)
 Smoked after only 2231 393 1.00 (0.86–1.16) 165 1.00 (0.81–1.24) 72 0.90 (0.65–1.24)
 1–5 1199 198 0.98 (0.81–1.18) 96 0.94 (0.73–1.21) 47 0.98 (0.68–1.42)
 6–9 495 94 1.11 (0.86–1.43) 50 1.16 (0.82–1.63) 24 1.42 (0.87–2.31)
 ≥10 390 85 1.20 (0.90–1.59) 26 0.93 (0.59–1.47) 12 1.04 (0.53–2.03)
 P for trendb 0.70 0.37 0.91
aAdjusted for age, study, time period, geographic region, education, age at menarche, age at first birth, parity, oral contraceptive use, estrogen only use, estrogen and 
progesterone use, body mass index, family history of breast cancer and alcohol consumption.
bExcluding never smokers.
cAmong parous women.
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toxic and carcinogenic effects. The mechanism for these associ-
ations is unknown but may involve more general effects on the 
hypothalamic–pituitary–adrenal axis (38). Therefore, cigarette 
smoking may not have the same effects on breast cancer risk in 
pre- and post-menopausal women (36,37).
Previous findings have been inconsistent on the association 
of smoking with breast cancer subtypes defined by hormone 
receptor status (6,7). Recent large cohort studies in Europe and 
the USA found an increased risk in current and former smokers 
for ER+ but not for ER− breast cancer, although the interaction 
tests were not statistically significant (5,26). A population-based 
case–control study of young women in the USA found that ever 
smokers had an increased risk of ER+ but not of triple-negative 
breast cancer (30). A case–control study in Japan reported that 
women who start to smoke as teenagers might have a higher 
risk of postmenopausal ER−/PR− cancer (39). In our study, the 
association of smoking with postmenopausal cancer risk was 
somewhat stronger for ER+ than for ER− cancer. Cigarette smok-
ing has direct carcinogenic effects in breast tissue, since mam-
mary carcinogens in cigarette smoke can reach breast tissue (40), 
form DNA adducts and cause mutations (41,42). These effects 
may explain the increased risk observed among postmenopau-
sal women in our study. Also, carcinogens in tobacco smoke 
can have both estrogenic and anti-estrogenic effects (30,36,43). 
Therefore, the effects of tobacco smoke on breast cancer risk via 
estrogen metabolism are not straightforward.
To our knowledge, no study other than those participating in 
the AMBER Consortium reported the association between smoking 
and breast cancer risk in an African American population. CBCS 
previously found a stronger association in African Americans than 
in whites (11). BWHS reported an increased risk of premenopau-
sal ER+ breast cancer associated with active smoking, especially 
smoking at younger age and higher pack-years (12). MEC and 
WCHS did not report separately on African American women.
Strengths of our study include a large sample size and 
a wide range of covariates. The AMBER Consortium offers a 
unique opportunity to assess risk factors for specific subtypes 
of breast cancer and subgroups in African American women 
with adequate statistical power. A  limitation is that we were 
not able to examine exposure to passive smoking for the entire 
dataset, because MEC did not collect data on it. However, when 
we ran the analysis limited to women with secondhand smok-
ing information, no significant association was found with pas-
sive smoking. We were not able to consider duration or intensity 
of passive smoking due to insufficient information. Two of the 
four studies included in the analysis were case–control studies, 
which could be subject to recall bias and to underrepresenta-
tion of smokers among controls. Separate analyses of the case–
control studies and the original cohort studies did not provide 
evidence of such bias. Another limitation is that HER2 data were 
missing for many participants, since testing for HER2 expression 
did not become widespread until 2005. ER status was also miss-
ing for a substantial proportion (20%) of subjects, which may 
lead to bias in risk estimates.
In conclusion, we found an increased risk of postmenopau-
sal breast cancer associated with long duration and greater 
pack-years of smoking in African American women, possibly 
stronger for ER+ cancer, but a decreased risk of premenopausal 
breast cancer in former and current smokers.
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